Fecal microbiota transplant to treat ICU delirium

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional, single-center trial administers an intestinal microbiota suspension (fecal microbiota transplantation) to adult ICU patients with CAM-ICU–positive delirium who are expected to remain in the ICU at least five days. Key inclusion criteria are age ≥18, a positive CAM-ICU delirium assessment, and signed informed consent; routine long-term antipsychotic use and other contraindications are excluded. Participants will be monitored for changes in delirium duration, ICU and hospital length of stay, and short- to medium-term cognitive outcomes. The trial is conducted in the Department of Critical Care Medicine at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Age ≥ 18 years old, no ethnic or gender restrictions;
* 2\. CAM-ICU-positive delirium;
* 3\. Expected ICU stay ≥ 5 days after inclusion in the study;
* 4\. Signed written informed consent.

Exclusion Criteria:

* 1\. Routine administration of antipsychotic medications: Conventional antipsychotic therapy refers to the daily ingestion or application of any sustained-release formulation (in any dosage form) of antipsychotic drugs with the ATC code N05A (in any form), including the following agents:

  1. Typical antipsychotics: Chlorprothixene, Flupentixol, Haloperidol, Levomepromazine, Loxapine, Melperone, Perphenazine, Pericyazine, Pimozide, Prochlorperazine, Zuclopenthixol, Pimavanserin, Sulpiride.
  2. Atypical antipsychotics: Amisulpride, Aripiprazole, Asenapine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Sertindole, Ziprasidone. However, the non-habitual administration of antipsychotic medications in the general ward prior to the patient's ICU admission (e.g., for the management of delirium) is deemed acceptable. Nevertheless, antipsychotic therapy should be discontinued upon the patient's ICU admission.
* 2\. Severe systemic infection in the early stage of resuscitation, hemodynamic instability or insufficient tissue perfusion, and severe imbalance of water, electrolyte and acid-base.
* 3\. Patients with a high risk of death within 5 days as judged by the clinician, or those whose treatment decisions are restricted.
* 4\. Active major gastrointestinal bleeding, perforation, or other severe damage to the intestinal barrier.
* 5\. Patients who cannot tolerate 50% of their caloric requirements through enteral nutrition due to severe diarrhea, significant fibrotic intestinal stenosis, severe gastrointestinal bleeding, or high-flow enteric fistula.
* 6\. Planned or recent abdominal surgery (within 14 days).
* 7\. Currently diagnosed with fulminant colitis or toxic megacolon.
* 8\. Recently received high-risk immunosuppressive or cytotoxic drug treatment: such as rituximab, doxorubicin, or medium to high-dose corticosteroids (20 mg/d prednisone or higher) for more than 4 weeks.
* 9\. Pregnant or lactating women.
* 10\. Participated in other clinical trials as a subject within the past 3 months or at the time of enrollment.
* 11\. Delirium assessment non applicable: this includes language barriers (patients with foreign language where delirium assessment cannot be confidently performed by the site staff), patients who are deaf, blind or aphasic. Comatose patients are not applicable for delirium assessment. Coma is defined by the following levels of consciousness: RASS -4 to -5. Further, RASS -3 may be considered as coma if this is the judgement of the treating physician. If a patient's coma is considered related to administration of sedative agents, an effort should be made to reduce or terminate the sedative treatment, according to the clinician's discretion.
* 12\. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that limit the validity of informed consent for participation in this study.

Where it's running

• Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, China Recruiting

Study contacts

• Study coordinator: Jiancheng Zhang
• Email: zhjcheng1@126.com
• Phone: 8613554105815

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can citicoline help prevent cognitive decline after delirium in older adults with hip fracture?

  This study tests whether taking citicoline for 6 months after discharge helps prevent cognitive decline in adults 65 and older who had delirium during hospitalization for hip fracture.

  Recruiting Phase 2 University of Milano Bicocca · Monza, Monza E Brianza · NCT07804498

• Delirium and Light: Exploring Modifiable Risk Factors in Critically Ill Adults

  This pilot observational study tests whether circadian-light factors influence delirium risk in adults recovering in critical care.

  Recruiting King's College Hospital NHS Trust · London · NCT07791472

• VR-based cognitive games to help prevent delirium after big surgery

  A VR-based cognitive stimulation game is being tested to see if it can help prevent delirium in adults 65 and older after major surgery.

  Recruiting at 2 sites The Methodist Hospital Research Institute · Houston, Texas and 1 other locations · NCT07641153

• Computer-assisted cognitive stimulation for delirium in older adults

  This will try adding tablet-based cognitive exercises to sleep and mobility support to see if they reduce delirium in people aged 60 and older in subacute care.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Reus, Tarragona · NCT07563244

• Letting patients drink clear fluids until called to the operating room to shorten pre-surgery fasting

  This project will try letting elective procedure patients drink clear liquids until they're called to the operating room to see if fasting times, comfort, and perioperative outcomes improve.

  Recruiting University of Giessen · Giessen · NCT07488468

• Lemborexant to help Sleep and Delirium in older ICU patients

  This study tests whether lemborexant, a sleep medication, helps improve sleep and reduce delirium in adults 65 and older in the ICU.

  Recruiting Phase 4 Mahidol University · Bangkok · NCT07407400

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.